Procurement-focused guidance on using nuclease to reduce residual DNA/RNA, lower lysate viscosity, improve clarification, and protect downstream protein purification performance.
Protein recovery is often limited by what comes out of the cell along with the target protein. Genomic DNA, RNA, plasmid fragments, and other nucleic acid material can turn a lysate into a viscous, difficult-to-clarify stream that slows centrifugation, loads depth filters aggressively, and compromises downstream chromatography behavior.
Strandfall Nuclease is used to degrade DNA and RNA into smaller fragments during protein extraction and clarification workflows. The operational result is a process stream that is easier to mix, pump, clarify, filter, and purify.

For B2B teams, the value is practical: less viscosity, fewer clarification bottlenecks, improved downstream compatibility, and more predictable lot-to-lot handling.
Nuclease is commonly introduced after cell disruption or during controlled lysate conditioning, before high-load clarification steps. In many workflows, it becomes a process aid for reducing nucleic-acid-driven viscosity before the material reaches centrifuges, depth filters, membrane filters, capture columns, or polishing steps.
Typical use points include:
High-molecular-weight nucleic acids can make lysates stringy, shear-sensitive, and difficult to handle. Nuclease fragments DNA and RNA, reducing the structural contribution of nucleic acids to viscosity. This supports more consistent mixing, transfer, and hold-step performance.
When nucleic acid burden is high, solids separation becomes less efficient. Treated lysates often present as more manageable feeds to centrifugation, depth filtration, and membrane prefiltration. The objective is not simply a clearer appearance; it is a feed stream that behaves predictably under process conditions.
Residual nucleic acids can interfere with chromatography through nonspecific interactions, high backpressure, fouling, and inconsistent binding environments. Nuclease treatment helps reduce the nucleic acid load before capture or polishing, supporting more stable column operation and cleaner process development decisions.

Cell paste quality, harvest density, lysis intensity, and host strain behavior can shift nucleic acid burden from batch to batch. A defined nuclease treatment step gives manufacturing and process development teams another control point for stabilizing lysate properties before downstream purification.
Selecting nuclease for protein workflows is not only a product decision. It is a process-fit decision. Procurement, process development, and manufacturing teams should align on the following before scale-up.
Confirm the nuclease is suitable for the actual lysate environment: buffer system, salt level, pH range, temperature profile, detergent presence, reducing agents, protease inhibitors, and metal ion availability. Small formulation differences can influence treatment efficiency and hold-step behavior.
Nuclease is typically evaluated close to lysis or immediately after disruption, when nucleic acids are most available and before high-viscosity material burdens clarification equipment. Earlier addition can improve handling, but the best point depends on target protein stability, lysis method, and process constraints.
Nuclease acts on nucleic acids, but the surrounding process conditions still matter. Buyers should evaluate whether the treatment window, temperature exposure, and buffer package preserve target protein integrity, activity, solubility, and binding behavior.
Downstream teams should consider whether the nuclease itself must be removed, reduced, or documented at later purification stages. For many protein workflows, normal clarification and chromatography steps support removal, but acceptance criteria should be defined internally.

For production environments, documentation can matter as much as performance. Strandfall can support purchasing and quality review with product documentation appropriate to the intended use case, supply model, and qualification stage.
When disrupted biomass forms a thick lysate that resists transfer or clogs early-stage filters, nuclease treatment can reduce viscosity before clarification. This is especially useful when nucleic acids dominate the rheology of the process stream.
Depth filters and membrane filters can overload quickly when DNA/RNA remains associated with cellular debris. Nuclease treatment helps reduce nucleic acid entanglement and can make the feed more compatible with staged clarification.
Nucleic acid contamination can create noisy purification behavior, including nonspecific binding, unpredictable elution profiles, and pressure instability. Pre-column nuclease treatment supports a cleaner starting point for capture and polishing development.
A lysate that behaves acceptably at bench scale may become difficult at pilot or production scale. Nuclease treatment can be evaluated early as a scale-up control for mixing, transfer, filtration, and purification consistency.
Use this checklist when qualifying nuclease for a protein workflow:
A strong technical quote should cover more than price. For a nuclease used in protein processing, request confirmation of:
Strandfall is built for technical buyers who need enzyme supply to connect with process outcomes. Our nuclease positioning is focused on controllable nucleic acid reduction, practical workflow integration, and procurement clarity.
You get a direct path to product fit discussions, quote support, and documentation review without unnecessary catalog noise.
If you are evaluating nuclease for nucleic acid removal in a protein workflow, share your process context and target use stage. Strandfall can help confirm fit, packaging options, documentation needs, and quote timing.
[Contact form: request a quote / get pricing]
Suggested form fields:
Submit the form to request a quote or get pricing from Strandfall.



Tell us your application and volume — we reply with pricing, specs, and lead time.